New Concept Car: Infiniti Etherea
It's a brave new dawn for Infiniti! Nissan's luxury arm has revealed official pictures of a bold new concept car, ahead of its debut at the Geneva Motor Show.
Called the ETHEREA, it's the Japanese firm's take on a luxury hatchback and previews how a future entry-level model could look. And if the concept's wild styling is anything to go by the production car will be the among the most distinctive in its class, which already includes the BMW 1-Series, Audi A3 and Lexus CT200h hybrid.
Using an evolution of the established design language, the ETHEREA's front end ties in neatly with the rest of the existing range, but the full-length panoramic roof and curved C-pillar, first seen on the Essence concept, give it a unique identity. Infiniti claims it blends elements of coupé, sedan, hatchback and even crossover into its design.
“ETHEREA is about a new type of luxury for younger buyers,” said Toru Saito, Corporate Vice President and Leader of the Global Infiniti Business Unit. “It is not just a smaller version of a typically conservative and traditional luxury car.”
More details about Infiniti's new baby will follow when it debuts in Geneva - we'll be there reporting live from the show floor. For more details click here.
Thanks to: Auto Express
New Car: 2012 Lancia Ypsilon
Say ciao baby to the latest fashion – the Italian-American supermini!
These are the first pictures of the new Lancia Ypsilon, which will debut at the Geneva Motor Show in March. It’s based on a stretched version of the Fiat 500 platform, and will be rebadged as a Chrysler in the US firm’s new UK line-up. The five-door will be one of two Italian-born Lancias – alongside the Delta – and will join the new US-built 300 saloon in dealers next year.
This is the third incarnation of the Ypsilon – which has never been sold here before. However, when it arrives in September, it promises low emissions and great luxury for its class. Two engines deliver sub-100g/km CO2 emissions – the 95bhp 1.3-litre diesel and 85bhp two-cylinder TwinAir petrol first seen on the 500. The entry unit is a 1.2 petrol making 65bhp.
The five-door is shorter than the Audi A1, but claims class-leading boot space, as well as a high-quality interior. With prices likely to start at around £13,000 – to compete with the A1 and the MINI – the Ypsilon is aiming to fulfil Chrysler’s promise to provide ‘affordable luxury’.
Lancia will take the wraps off its version of the 300 on the stands at Geneva. It will be badged Thema for Europe. And a new Flavia and Flavia convertible, based on the Chrysler 200, debut as well. For more details click here.
Thanks to: Auto Express
Thanks to: Auto Express
Kia Sportage Tops Small CUVs in Consumer Reports Test
AUTOBLOG.com - The 2011 Kia Sportage beat out both the Nissan Juke and Mitsubishi Outlander Sport in a recent CUV shootout conducted by Consumer Reports. According to CR, Kia has managed to more effectively straddle the line between a full-on SUV and a more civil hatchback with its offering...
Read More at Autoblog
Read More at Autoblog
Honda City New & Old Model
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Honda City
Novitec Rosso Race 606 based on Ferrari California
We've seen our fair share of tuning packages for the Ferrari California, but we may have a new contender for the best of the bunch.
Dubbed the Race 606, the car features a front lip spoiler, a ventilated hood, an aggressive rear diffuser, and plenty of carbon fiber accents. Other goodies include a lowered sport suspension (which reduces the ride height by 35mm), a hydraulic front lift system, and three-piece NF3 wheels with Pirelli PZero tires.
Under the hood, the 4.3-liter V8 has been outfitted with a supercharger, an intercooler, a new intake manifold, larger fuel injectors, a revised ECU, and a high-pNovitec Rosso Race 606, Novitec Rosso Race 606, Novitec Rosso California, Novitec Rosso, Ferrari California, California, Ferrari tuners, Ferrari tuning, California tuners, California tuerformance exhaust system. Thanks to these tweaks, the engine produces 606 PS (446 kW / 598 hp) and 603 Nm (445 lb-ft) of torque - an increase of 146 PS (107 kW / 144 hp) and 118 Nm (87 lb-ft). This enables the roadster to accelerate from 0-100 km/h in 3.8 seconds, before hitting a top speed of 325 km/h (202 mph).
No word on pricing, but the Novitec Rosso Race 606 will be officially unveiled at the Geneva Motor Show.
Source: Novitec Rosso
2011 Stock Picks: Cambiar Small Cap (CAMSX),Novavax (NVAX)
2011 Stock Picks: Cambiar Small Cap (CAMSX)
What are our favorite funds for 2011? Among US funds, we particularly like Cambiar Small Cap (CAMSX); the fund combines many characteristics for long-term success with good positioning for the current investment environment.
Cambiar Small Cap is managed by Andy Baumbusch and Jeff Susman. Baumbusch specializes in the analysis of industrial, media and telecommunications stocks. Susman specializes in the consumer-discretionary and technology sectors.
In 2010, their efforts produced a total return of 35.7%, among the top performances of all the funds we track.
Permalink: [632] Top Stocks To Buy - 2011 Stock Picks: Cambiar Small Cap (CAMSX),Novavax (NVAX)
And, they aren’t looking for stocks that are just a little cheap, historically speaking. They search out stocks whose valuations fall in the bottom 25% or so of these historical ranges.
In this way, they hope to increase the odds of picking stocks that gain at least 50% over the next 12 to 24 months, which is their goal for performance.
One key to doing so, they believe, is to find companies that are likely to benefit from near-term catalysts including new products and services, or from restructuring, such as the closing of an unprofitable business unit or product line.
We also like how the fund’s current sector weightings shake out from the managers’bottom-up (i.e., stock by stock) stock picking.
Cambiar Small Cap has especially large allocations to industrials and technology, whichh are among our favorite sectors for equity investment in 2011.
2011 Stock Picks: Novavax (NVAX)
Novavax (NVAX), one of our new buys last year, has basically been flat since our initial recommendation at $2.44.
The stock was recommended because we believe that they are a industry leader in the development, manufacture, and commercialization of innovative vaccines for a variety of viral diseases.
The company is currently testing two vaccines based on its virus-like particle (VLP) technology in late stage trials; vaccines for seasonal and pandemic influenza are in Phase II and the company is preparing for Phase III trials.
We believe that NVAX has substantial potential to develop a vaccine platform based on their VLP technology.
NVAX has differentiated itself from its competitors within the vaccine development space with a proven management team, including CEO Dr. Rahul Singvhi, a recognized vaccine industry leader.
He has worked in vaccines for entire career, including substantial experince at vaccine-giant Merck.
When we recommended NVAX, we said we exepcted the following events to occur for NVAX.
First, we expect the company to receive a government contract in the $100+ million range that will be used to finish developing and bring both their pandemic and seasonal flu vaccines to the market.
Then in the Q1 of 2011 we expect NVAX to start a Phase 1 clinic trial for their respiratory syncytial virus (RSV) vaccine to prevent infection in neonates and the elderly.
We are still waiting for the government contract, which we still exepct at any time. The Phase I RSV trial recently starte.
The trial is a blinded, placebo-controlled, escalating-dose study of healthy adults 18 to 49 years old, a total of 100 subjects will be allocated to four cohorts and randomized to receive vaccine treatment or saline placebo in a 4:1 ratio.
It is expected that interim top-line data from the trial will be available in the third quarter of 2011.
We want to emphasize that this is a substantial market opportunity with very large potential sales around the world.
For example, the passive RSV vaccine Synagis for just infants exceeded $1 billion in sales in 2009.
There are currently no cost-effective measures for protecting elderly people against RSV, so a new solution would significantly enlarge what is already a billion dollar market. NVAX is a buy under $3.
What are our favorite funds for 2011? Among US funds, we particularly like Cambiar Small Cap (CAMSX); the fund combines many characteristics for long-term success with good positioning for the current investment environment.
Cambiar Small Cap is managed by Andy Baumbusch and Jeff Susman. Baumbusch specializes in the analysis of industrial, media and telecommunications stocks. Susman specializes in the consumer-discretionary and technology sectors.
In 2010, their efforts produced a total return of 35.7%, among the top performances of all the funds we track.
Permalink: [632] Top Stocks To Buy - 2011 Stock Picks: Cambiar Small Cap (CAMSX),Novavax (NVAX)
And, they aren’t looking for stocks that are just a little cheap, historically speaking. They search out stocks whose valuations fall in the bottom 25% or so of these historical ranges.
In this way, they hope to increase the odds of picking stocks that gain at least 50% over the next 12 to 24 months, which is their goal for performance.
One key to doing so, they believe, is to find companies that are likely to benefit from near-term catalysts including new products and services, or from restructuring, such as the closing of an unprofitable business unit or product line.
We also like how the fund’s current sector weightings shake out from the managers’bottom-up (i.e., stock by stock) stock picking.
Cambiar Small Cap has especially large allocations to industrials and technology, whichh are among our favorite sectors for equity investment in 2011.
2011 Stock Picks: Novavax (NVAX)
Novavax (NVAX), one of our new buys last year, has basically been flat since our initial recommendation at $2.44.
The stock was recommended because we believe that they are a industry leader in the development, manufacture, and commercialization of innovative vaccines for a variety of viral diseases.
The company is currently testing two vaccines based on its virus-like particle (VLP) technology in late stage trials; vaccines for seasonal and pandemic influenza are in Phase II and the company is preparing for Phase III trials.
We believe that NVAX has substantial potential to develop a vaccine platform based on their VLP technology.
NVAX has differentiated itself from its competitors within the vaccine development space with a proven management team, including CEO Dr. Rahul Singvhi, a recognized vaccine industry leader.
He has worked in vaccines for entire career, including substantial experince at vaccine-giant Merck.
When we recommended NVAX, we said we exepcted the following events to occur for NVAX.
First, we expect the company to receive a government contract in the $100+ million range that will be used to finish developing and bring both their pandemic and seasonal flu vaccines to the market.
Then in the Q1 of 2011 we expect NVAX to start a Phase 1 clinic trial for their respiratory syncytial virus (RSV) vaccine to prevent infection in neonates and the elderly.
We are still waiting for the government contract, which we still exepct at any time. The Phase I RSV trial recently starte.
The trial is a blinded, placebo-controlled, escalating-dose study of healthy adults 18 to 49 years old, a total of 100 subjects will be allocated to four cohorts and randomized to receive vaccine treatment or saline placebo in a 4:1 ratio.
It is expected that interim top-line data from the trial will be available in the third quarter of 2011.
We want to emphasize that this is a substantial market opportunity with very large potential sales around the world.
For example, the passive RSV vaccine Synagis for just infants exceeded $1 billion in sales in 2009.
There are currently no cost-effective measures for protecting elderly people against RSV, so a new solution would significantly enlarge what is already a billion dollar market. NVAX is a buy under $3.
Who's Next in the Exchange Merger Mania?
On Wednesday of last week, the Deutsche Boerse announced that it was in advanced talks with NYSE Euronext (NYX) to combine into the world's largest exchange. This came just hours after the London Stock Exchange (LSE) announced its merger with the TMX Group, which runs the Toronto and Montreal exchanges.
Both of these mergers followed last year's proposed acquisition of the Australian Stock Exchange (ASX) by the Singapore stock exchange, which has yet to be approved by the Australian government, but appears to be making progress.
Of course, the NYSE/DB tie-up took center stage in the US since it is the only one easily accessible by US investors, and also because it was hailed as an assault on an American institution.
Permalink: [633] Top Stocks To Buy - Who's Next in the Exchange Merger Mania?
Come on people, the nostalgia is nice and all, but this is about dollars and cents, not baseball and Mom's apple pie. According to the NYSE February 8 earnings conference call, only 53% of its revenue was dollar denominated, while 47% was either pound or euro denominated. It probably would have been closer to 50/50 if they didn't have to account for $19 million in unfavorable currency translations.
Synergies and Survival
Both boards are expected to approve the deal this week; then it will be in the hands of the regulators. Surprisingly, it might be European regulators who raise objections, since the combination of Deutsche Boerse and Euronext operations will effectively control nearly all European futures trading and may require separating the clearing and trading portions of the merged company.
Regardless of regulatory outcomes, it's worth taking a look at what is motivating the potential merger. Exchanges worldwide have experienced margin pressures in the equities business as the advent of electronic exchanges has sliced execution costs to the bone. For now, the futures and options business is where the money is, and the pot is growing.
According to the Options Clearing Corporation, average daily contract volume in options has grown from 5.9 million contracts per day in 2005 to 15.6 million contracts in 2010, while futures volume has increased from 22,600 contracts per day in 2005 to 105,600 contracts per day in 2010. And 2011 is off to a rip roaring start at 18.9 million option contracts per day and 153,800 futures contracts per day.
As exchanges continue to move from floor based operations to electronic trading, volume is everything. The few extra electrons it takes to send an additional order to an electronic exchange is minimal from the exchange's cost perspective, so the bigger the exchange, the greater the volume and the larger the margins.
Additionally, the combined exchange will offer previously unavailable ease of access to markets across the pond. It is likely to become much less complex for the US investor to access European markets, and vice versa. Again, another avenue for increasing volumes.
The Deutsche Boerse is projecting synergies of $410 million from increased volumes and cost cutting in redundant divisions.
Who's Next?
You would think that this would be an easy question, since there are only four publically traded US exchanges: CBOE Holdings (CBOE), The CME Group (CME), The Intercontinental Exchange (ICE), and the Nasdaq OMX Group (NDAQ). However, both Hong Kong and Tokyo have indicated that they would consider combinations, and the upstart BATS Exchange is not publicly traded.
BATS (Better Alternative Trading Systems), a Kansas based ECN, came into existence in 2005 and has since jumped to third in equity volume market share, behind the Nasdaq and NYSE, and its options business is growing strong.
Additionally, on the futures side, ELX Futures has been growing in the Eurodollar and interest rate space. ELX was created in 2007 by a consortium including Bank of America, Barclays Capital, Citi, Credit Suisse, Deutsche Bank, Goldman Sachs, JP Morgan, Goldman Sachs and 5 others.
The table below provides a quick comparison between the publicly listed options and the current value of the NYSE.
What is striking is how far these stocks are from their all-time highs. Even if the Deutsche/NYSE deal crests $40, it is still a far cry from its 2006 peak of $112. And the CBOE, which went public in June 2010, has yet to recover its IPO price of $29. This just goes to show what a tough business being an exchange is.
Nevertheless, we have to look forward, and NDAQ certainly has the best earnings outlook and a very digestible market cap. Additionally, the stock has been strong since the October announcement of the Singapore/ASX deal. The market seems to have a lot of faith in this one.
The CBOE has held up rather well since the lock up expired in mid-December. It is clearly the cheapest on the board, and could bring $3-$3.5 billion in the best case scenario. Also the CBOE owns the VIX and other branded products, but mergers of late have been about synergies, volumes, and cost savings, and it's not clear what they offer on that front. Notably, volume declined 2% in the most recent quarter compared to the year ago quarter.
The CME dominates the US futures markets, which makes it attractive, but its size might make it more of an acquirer rather that an acquiree.
Finally, the ICE is interesting, though not talked about as much. The company beat estimates in last week's earnings release and is growing its presence as a credit derivatives clearing house. Price wise it has held up well and management has a history of executing well.
There is no question that another tie-up or two in the exchange sector is likely on the horizon, but which players will be at the table is still up for discussion.
Both of these mergers followed last year's proposed acquisition of the Australian Stock Exchange (ASX) by the Singapore stock exchange, which has yet to be approved by the Australian government, but appears to be making progress.
Of course, the NYSE/DB tie-up took center stage in the US since it is the only one easily accessible by US investors, and also because it was hailed as an assault on an American institution.
Permalink: [633] Top Stocks To Buy - Who's Next in the Exchange Merger Mania?
Come on people, the nostalgia is nice and all, but this is about dollars and cents, not baseball and Mom's apple pie. According to the NYSE February 8 earnings conference call, only 53% of its revenue was dollar denominated, while 47% was either pound or euro denominated. It probably would have been closer to 50/50 if they didn't have to account for $19 million in unfavorable currency translations.
Synergies and Survival
Both boards are expected to approve the deal this week; then it will be in the hands of the regulators. Surprisingly, it might be European regulators who raise objections, since the combination of Deutsche Boerse and Euronext operations will effectively control nearly all European futures trading and may require separating the clearing and trading portions of the merged company.
Regardless of regulatory outcomes, it's worth taking a look at what is motivating the potential merger. Exchanges worldwide have experienced margin pressures in the equities business as the advent of electronic exchanges has sliced execution costs to the bone. For now, the futures and options business is where the money is, and the pot is growing.
According to the Options Clearing Corporation, average daily contract volume in options has grown from 5.9 million contracts per day in 2005 to 15.6 million contracts in 2010, while futures volume has increased from 22,600 contracts per day in 2005 to 105,600 contracts per day in 2010. And 2011 is off to a rip roaring start at 18.9 million option contracts per day and 153,800 futures contracts per day.
As exchanges continue to move from floor based operations to electronic trading, volume is everything. The few extra electrons it takes to send an additional order to an electronic exchange is minimal from the exchange's cost perspective, so the bigger the exchange, the greater the volume and the larger the margins.
Additionally, the combined exchange will offer previously unavailable ease of access to markets across the pond. It is likely to become much less complex for the US investor to access European markets, and vice versa. Again, another avenue for increasing volumes.
The Deutsche Boerse is projecting synergies of $410 million from increased volumes and cost cutting in redundant divisions.
Who's Next?
You would think that this would be an easy question, since there are only four publically traded US exchanges: CBOE Holdings (CBOE), The CME Group (CME), The Intercontinental Exchange (ICE), and the Nasdaq OMX Group (NDAQ). However, both Hong Kong and Tokyo have indicated that they would consider combinations, and the upstart BATS Exchange is not publicly traded.
BATS (Better Alternative Trading Systems), a Kansas based ECN, came into existence in 2005 and has since jumped to third in equity volume market share, behind the Nasdaq and NYSE, and its options business is growing strong.
Additionally, on the futures side, ELX Futures has been growing in the Eurodollar and interest rate space. ELX was created in 2007 by a consortium including Bank of America, Barclays Capital, Citi, Credit Suisse, Deutsche Bank, Goldman Sachs, JP Morgan, Goldman Sachs and 5 others.
The table below provides a quick comparison between the publicly listed options and the current value of the NYSE.
What is striking is how far these stocks are from their all-time highs. Even if the Deutsche/NYSE deal crests $40, it is still a far cry from its 2006 peak of $112. And the CBOE, which went public in June 2010, has yet to recover its IPO price of $29. This just goes to show what a tough business being an exchange is.
Nevertheless, we have to look forward, and NDAQ certainly has the best earnings outlook and a very digestible market cap. Additionally, the stock has been strong since the October announcement of the Singapore/ASX deal. The market seems to have a lot of faith in this one.
The CBOE has held up rather well since the lock up expired in mid-December. It is clearly the cheapest on the board, and could bring $3-$3.5 billion in the best case scenario. Also the CBOE owns the VIX and other branded products, but mergers of late have been about synergies, volumes, and cost savings, and it's not clear what they offer on that front. Notably, volume declined 2% in the most recent quarter compared to the year ago quarter.
The CME dominates the US futures markets, which makes it attractive, but its size might make it more of an acquirer rather that an acquiree.
Finally, the ICE is interesting, though not talked about as much. The company beat estimates in last week's earnings release and is growing its presence as a credit derivatives clearing house. Price wise it has held up well and management has a history of executing well.
There is no question that another tie-up or two in the exchange sector is likely on the horizon, but which players will be at the table is still up for discussion.
Betting on Lower Gold Prices
The Spyder Gold Trust (GLD) challenged the 50% retracement resistance last Wednesday but has been unable to move much higher. A majority of investors are still long gold, and while the major trend is positive, I am still expecting lower prices over the next month or so. This is the week that gold could turn lower. So is there a good way to bet on lower gold prices?
Click to Enlarge
Chart Analysis: The weekly chart of GLD shows that it has closed higher for the past two weeks. Rallies against the trend often only last for two bars.
* The key 61.8% resistance is at $135.05, which still could be tested before the rally reverses
* A drop below key short-term support at $131.25 will indicate the rebound is over
* Further chart support is at $129.25 with initial Fibonacci support at $125.40 - $126.40
* The weekly on-balance volume (OBV) formed a negative divergence at the recent highs and has broken its uptrend. It rebounded, but it is still below its declining weighted moving average (WMA). This is consistent with a failing rally
* The monthly OBV confirmed the recent highs, so the major trend is positive
Permalink: [634] Top Stocks To Buy - Betting on Lower Gold Prices
The Powershares DB Gold Double Short ETN (DZZ) is a bet against lower gold prices that may not be appropriate for all investors due to its risk. (See the Powershares Web site here). Technically, DZZ appears to be completing a bottom formation but needs to move through key resistance at $9.30 to confirm that the lows are in place.
* From the December lows at $7.88, DZZ rallied to a high of $9.26
* The 50% support level of this rally is now being tested with the 61.8% support at $8.40
* There is further support at the gap between $8.08 and $8.26
* The daily OBV surged in early January and is acting much stronger than prices, which is consistent with a bottom formation
* Volume has contracted on the pullback
* The 38.2% resistance from the July highs is at $9.23 with the 50% resistance at $10.07
What It Means:As I mentioned last week, this still looks like a rally within the downtrend for gold futures, GLD, and the Market Vectors Gold Miners ETF (GDX). Therefore, all three should drop below the lows made at the end of January. From my in-depth article on the correction (see Gold and Silver: How Low Will They Go), I still have a first downside target for GLD at $125.40 - $126.40 and then the $123.20 - $121 area, as represented by the green box on the above chart.
How to Profit: Before the rebound in gold is completed, we may see a brief drop and then one more rally above the recent highs, but a lower close is likely this week. Previously, I recommended hedging long positions in GLD by selling the March 130 calls against long holdings in the ETF. These were established at around $4.15 and they closed on Friday at $3.75. This is still the favored strategy if you have a long position in GLD.
An alternative way to offset a potential loss in your long gold position or take a speculative trade is to buy DZZ at $8.56 or better with a stop at $8.11. The first target is in the $10 area. Remember that these ETNs are very speculative and are meant to be held only for the short term.
The iShares Silver Trust (SLV) exceeded all Fibonacci retracement levels, but if my view on gold is correct, the rally in SLV should also fail, but I have no position or recommendation on SLV for now.
Click to Enlarge
Chart Analysis: The weekly chart of GLD shows that it has closed higher for the past two weeks. Rallies against the trend often only last for two bars.
* The key 61.8% resistance is at $135.05, which still could be tested before the rally reverses
* A drop below key short-term support at $131.25 will indicate the rebound is over
* Further chart support is at $129.25 with initial Fibonacci support at $125.40 - $126.40
* The weekly on-balance volume (OBV) formed a negative divergence at the recent highs and has broken its uptrend. It rebounded, but it is still below its declining weighted moving average (WMA). This is consistent with a failing rally
* The monthly OBV confirmed the recent highs, so the major trend is positive
Permalink: [634] Top Stocks To Buy - Betting on Lower Gold Prices
The Powershares DB Gold Double Short ETN (DZZ) is a bet against lower gold prices that may not be appropriate for all investors due to its risk. (See the Powershares Web site here). Technically, DZZ appears to be completing a bottom formation but needs to move through key resistance at $9.30 to confirm that the lows are in place.
* From the December lows at $7.88, DZZ rallied to a high of $9.26
* The 50% support level of this rally is now being tested with the 61.8% support at $8.40
* There is further support at the gap between $8.08 and $8.26
* The daily OBV surged in early January and is acting much stronger than prices, which is consistent with a bottom formation
* Volume has contracted on the pullback
* The 38.2% resistance from the July highs is at $9.23 with the 50% resistance at $10.07
What It Means:As I mentioned last week, this still looks like a rally within the downtrend for gold futures, GLD, and the Market Vectors Gold Miners ETF (GDX). Therefore, all three should drop below the lows made at the end of January. From my in-depth article on the correction (see Gold and Silver: How Low Will They Go), I still have a first downside target for GLD at $125.40 - $126.40 and then the $123.20 - $121 area, as represented by the green box on the above chart.
How to Profit: Before the rebound in gold is completed, we may see a brief drop and then one more rally above the recent highs, but a lower close is likely this week. Previously, I recommended hedging long positions in GLD by selling the March 130 calls against long holdings in the ETF. These were established at around $4.15 and they closed on Friday at $3.75. This is still the favored strategy if you have a long position in GLD.
An alternative way to offset a potential loss in your long gold position or take a speculative trade is to buy DZZ at $8.56 or better with a stop at $8.11. The first target is in the $10 area. Remember that these ETNs are very speculative and are meant to be held only for the short term.
The iShares Silver Trust (SLV) exceeded all Fibonacci retracement levels, but if my view on gold is correct, the rally in SLV should also fail, but I have no position or recommendation on SLV for now.
Lotus Exige Scura 2010 Cars Wallpapers And Previews
Lotus Exige Scura 2010 Cars Wallpapers And Previews Also we will uplaod More images.
This stunning special edition Lotus Exige Scura - "dark" in Italian - is due to make its grand debut at this year's Tokyo International Motorshow starting from today.
The stealth-looking Exige features a dramatic soft-feel matte black paint finish, high gloss 'Phantom Black' triple stripes running the length of the car and lightweight carbon fibre for the front splitter, oil cooler inlet vanes, side airscoops and rear spoiler.
This stunning special edition Lotus Exige Scura - "dark" in Italian - is due to make its grand debut at this year's Tokyo International Motorshow starting from today.
The stealth-looking Exige features a dramatic soft-feel matte black paint finish, high gloss 'Phantom Black' triple stripes running the length of the car and lightweight carbon fibre for the front splitter, oil cooler inlet vanes, side airscoops and rear spoiler.
BMW 120d Coupe Automatic Cars wallpapers and sepcification with prices
New BMW 120d Coupe Automatic Cars wallpapers and sepcification with pricesc R 306,500.00
New BMW 120d Coupe Cars Images And Specification With Prices
New BMW 120d Coupe Cars Images And Specification With Prices R 292,000.00
2007 BMW 120d Coupé dimensions & weight
Wheelbase 2660 mm 104.7 in
Track front 1474 mm 58 in
rear 1507 mm 59.3 in
Length 4360 mm 171.7 in
Width 1748 mm 68.8 in
Height 1423 mm 56 in
Length:wheelbase ratio 1.64
Ground clearance
Kerb weight 1450 kg 3197 lb
Weight distribution
(Front)
Fuel capacity 51 litres 11.2 UK Gal 13.5 US Gal
2007 BMW 120d Coupé dimensions & weight
Wheelbase 2660 mm 104.7 in
Track front 1474 mm 58 in
rear 1507 mm 59.3 in
Length 4360 mm 171.7 in
Width 1748 mm 68.8 in
Height 1423 mm 56 in
Length:wheelbase ratio 1.64
Ground clearance
Kerb weight 1450 kg 3197 lb
Weight distribution
(Front)
Fuel capacity 51 litres 11.2 UK Gal 13.5 US Gal
BMW 130i 5-Door Automatic Cars Wallpapers And prices
BMW 130i 5-Door Automatic Cars Wallpapers And prices
BMW 130i Automatic dimensions & weight
Wheelbase 2660 mm 104.7 in
Track front 1474 mm 58 in
rear 1487 mm 58.5 in
Length 4239 mm 166.9 in
Width 1748 mm 68.8 in
Height 1421 mm 55.9 in
Length:wheelbase ratio 1.59
Ground clearance 145 mm 5.7 in
Kerb weight 1485 kg 3274 lb
Weight distribution
(Front)
Fuel capacity 53 litres 11.7 UK Gal 14 US Gal
BMW 130i 5-Door Automatic R 332,200.00
BMW 130i Automatic dimensions & weight
Wheelbase 2660 mm 104.7 in
Track front 1474 mm 58 in
rear 1487 mm 58.5 in
Length 4239 mm 166.9 in
Width 1748 mm 68.8 in
Height 1421 mm 55.9 in
Length:wheelbase ratio 1.59
Ground clearance 145 mm 5.7 in
Kerb weight 1485 kg 3274 lb
Weight distribution
(Front)
Fuel capacity 53 litres 11.7 UK Gal 14 US Gal
BMW 130i 5-Door Automatic R 332,200.00
bmw cars best new 2010 top pics 2008
The BMW Art Car Project was introduced by the French racecar driver and auctioneer Hervé Poulain, who wanted to invite an artist to create a canvas on an automobile. It was in 1975, when Poulain commissioned American artist and friend Alexander Calder to paint the first BMW Art Car. This first example would be a BMW 3.0 CSL which Poulain himself would race in the 1975 Le Mans endurance race. Since Calder's work of art, many other renowned artists throughout the world have created BMW Art Cars, including David Hockney, Jenny Holzer, Roy Lichtenstein, Robert Rauschenberg, Frank Stella, and Andy Warhol. To date, a total of 17 BMW Art Cars, based on both racing and regular production vehicles, have been created. The most recent artist to the join BMW Art Car program is Jeff Koons in 2010 with his M3 GT2, which competed in the 2010 24 Hours of Le Mans but did not finish.. Artists for the BMW Art Car Project are chosen by a panel of international judges.According to Thomas Girst, who has been in charge of the BMW Art Cars project since 2004, the purpose of the project has changed over time: "In the beginning the cars were raced. There wasn't much of a public relations effort around them... Since then, some of the Art Cars have been used in advertisements to show that BMW is a player in the arts. With the Eliason work, part of what we are doing is raising awareness of alternative and renewable energy sources
* 1 BMW Art Cars
* 2 Miniatures
* 3 Public display
* 4 References
* 5 External links
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
* 1 BMW Art Cars
* 2 Miniatures
* 3 Public display
* 4 References
* 5 External links
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
bmw cars
2012 Hyundai Equus Gains Standard 5.0L V8 and Eight-Speed Automatic
Hyundai launched its Equus full-size sedan in the U.S. as a 2011 model with a 385-horsepower, 4.6-liter V-8 as the sole engine. For 2012, the Equus gets a significant horsepower bump, thanks to a new 429-hp, 5.0-liter V-8 that becomes the standard engine. The 2012 Equus hits dealerships this summer.
With the new engine comes a new transmission. The 4.6-liter V-8 paired with a six-speed automatic, but the 5.0-liter V-8 works with an eight-speed automatic transmission developed by Hyundai. The 2011 Equus achieves an EPA-estimated 16/24 mpg city/highway, but gas mileage figures — as well as any change in pricing — haven't been announced for the new drivetrain.
It's not every day that an automaker launches a car one year and gives it a new engine the next, but with the Equus' little brother, the Genesis sedan, adding the 5.0-liter V-8 as an optional engine for 2012, Hyundai had to take care of its flagship car, too.
With the new engine comes a new transmission. The 4.6-liter V-8 paired with a six-speed automatic, but the 5.0-liter V-8 works with an eight-speed automatic transmission developed by Hyundai. The 2011 Equus achieves an EPA-estimated 16/24 mpg city/highway, but gas mileage figures — as well as any change in pricing — haven't been announced for the new drivetrain.
It's not every day that an automaker launches a car one year and gives it a new engine the next, but with the Equus' little brother, the Genesis sedan, adding the 5.0-liter V-8 as an optional engine for 2012, Hyundai had to take care of its flagship car, too.
Subscribe to:
Posts (Atom)